https://vitalspanwire.com/news/alcohol-use-disorder-hospital-follow-up-evidence-reviewVitalspan Wireen2026-09-09T16:02:07.620ZReview finds weak evidence on connecting hospitalized alcohol-use patients to follow-up carehttps://vitalspanwire.com/news/rentosertib-protein-aging-clocks-lung-disease-studyVitalspan Wireen2026-09-09T11:02:22.340ZRentosertib study finds lower aging-clock estimates in lung-disease patientshttps://vitalspanwire.com/news/coya-303-mouse-inflammation-glp1-il2-studyVitalspan Wireen2026-09-08T21:02:20.301ZCOYA 303 study reports immune-signaling changes in mice exposed to inflammationhttps://vitalspanwire.com/news/ap1-immune-signaling-salt-sensitive-blood-pressureVitalspan Wireen2026-09-08T16:02:18.367ZStudy links immune-cell AP-1 signaling to salt-sensitive blood pressurehttps://vitalspanwire.com/news/personal-metabohealth-blood-score-prevention-studyVitalspan Wireen2026-09-08T11:02:05.981ZMetabolic blood score tracks disease risk, with mixed lifestyle-intervention resultshttps://vitalspanwire.com/news/menarini-bofanglutide-europe-licenseVitalspan Wireen2026-09-07T21:02:37.866ZMenarini licenses European rights to investigational GLP-1 drug bofanglutide